These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2493353)

  • 1. The metabolism of glyburide in subjects of known debrisoquin phenotype.
    Peart GF; Boutagy J; Shenfield GM
    Clin Pharmacol Ther; 1989 Mar; 45(3):277-84. PubMed ID: 2493353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.
    Dahl-Puustinen ML; Alm C; Bertilsson L; Christenson I; Ostman J; Thunberg E; Wikström I
    Br J Clin Pharmacol; 1990 Sep; 30(3):476-80. PubMed ID: 2121211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
    Peart GF; Boutagy J; Shenfield GM
    Eur J Clin Pharmacol; 1987; 33(4):397-402. PubMed ID: 3443146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers.
    Lennard MS; Tucker GT; Silas JH; Freestone S; Ramsay LE; Woods HF
    Clin Pharmacol Ther; 1983 Dec; 34(6):732-7. PubMed ID: 6641087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin.
    Woosley RL; Roden DM; Dai GH; Wang T; Altenbern D; Oates J; Wilkinson GR
    Clin Pharmacol Ther; 1986 Mar; 39(3):282-7. PubMed ID: 3081292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin.
    Steiner E; Alván G; Garle M; Maguire JH; Lind M; Nilson SO; Tomson T; McClanahan JS; Sjöqvist F
    Clin Pharmacol Ther; 1987 Sep; 42(3):326-33. PubMed ID: 3621788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically determined oxidation capacity and the disposition of debrisoquine.
    Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
    Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine.
    Leclercq V; Desager JP; Horsmans Y; Van Nieuwenhuyze Y; Harvengt C
    Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):593-8. PubMed ID: 2613393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin.
    Roy SD; Hawes EM; McKay G; Korchinski ED; Midha KK
    Clin Pharmacol Ther; 1985 Aug; 38(2):128-33. PubMed ID: 4017414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.
    Lledó P; Abrams SM; Johnston A; Patel M; Pearson RM; Turner P
    Eur J Clin Pharmacol; 1993; 44(1):63-7. PubMed ID: 8436157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.
    Spina E; Steiner E; Ericsson O; Sjöqvist F
    Clin Pharmacol Ther; 1987 Mar; 41(3):314-9. PubMed ID: 3816019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between uptake and elimination of toluene and debrisoquin hydroxylation polymorphism.
    Löf A; Hansen SH; Näslund P; Steiner E; Wallén M; Hjelm EW
    Clin Pharmacol Ther; 1990 Mar; 47(3):412-7. PubMed ID: 2311341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of debrisoquin phenotype on the inducibility of propranolol metabolism.
    Shaheen O; Biollaz J; Koshakji RP; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1989 Apr; 45(4):439-43. PubMed ID: 2702801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of chlorpropamide.
    Kallio J; Huupponen R; Pyykkö K
    Eur J Clin Pharmacol; 1990; 39(1):93-5. PubMed ID: 2276394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone.
    Nyberg S; Dahl ML; Halldin C
    Psychopharmacology (Berl); 1995 Jun; 119(3):345-8. PubMed ID: 7545821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].
    Dick B; Küpfer A; Molnàr J; Braunschweig S; Preisig R
    Schweiz Med Wochenschr; 1982 Jul; 112(30):1061-7. PubMed ID: 7123181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine.
    Yue QY; Hasselström J; Svensson JO; Säwe J
    Br J Clin Pharmacol; 1991 Jun; 31(6):635-42. PubMed ID: 1867957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cirrhosis and debrisoquin phenotype on the disposition and effects of pinacidil.
    Shaheen O; Patel J; Avant GR; Hamilton M; Wood AJ
    Clin Pharmacol Ther; 1986 Dec; 40(6):650-5. PubMed ID: 3780126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.
    Ward SA; Walle T; Walle UK; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1989 Jan; 45(1):72-9. PubMed ID: 2910639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.
    Llerena A; Alm C; Dahl ML; Ekqvist B; Bertilsson L
    Ther Drug Monit; 1992 Apr; 14(2):92-7. PubMed ID: 1585408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.